Review
doi: 10.12968/hmed.2009.70.11.45055.
Anti-tumour necrosis factor-alpha therapies in Crohn's disease
Affiliations
- PMID: 20081592
- DOI: 10.12968/hmed.2009.70.11.45055
Item in Clipboard
Review
Anti-tumour necrosis factor-alpha therapies in Crohn's disease
Br J Hosp Med (Lond).
2009 Nov.
Abstract
This article reviews the limitations of existing Crohn's disease therapies and the efficacy and safety of anti-tumour necrosis factor-alpha drugs. Trying to determine which patients may benefit from these therapies while minimizing toxicity is key. Special treatment situations and future developments are also briefly discussed.
Similar articles
-
Closing fistulas in Crohn's disease--should the accent be on maintenance or safety?N Engl J Med. 2004 Feb 26;350(9):934-6. doi: 10.1056/NEJMe048001. N Engl J Med. 2004. PMID: 14985492 No abstract available.
-
[Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].Z Gastroenterol. 2005 Jul;43(7):689-90. doi: 10.1055/s-2005-858274. Z Gastroenterol. 2005. PMID: 16001352 German. No abstract available.
-
How to manage difficult Crohn's disease: optimum delivery of anti-TNFs.Expert Rev Gastroenterol Hepatol. 2009 Aug;3(4):407-15. doi: 10.1586/egh.09.25. Expert Rev Gastroenterol Hepatol. 2009. PMID: 19673627 Review.
-
Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience.Aliment Pharmacol Ther. 2011 Apr;33(8):857-69. doi: 10.1111/j.1365-2036.2011.04598.x. Epub 2011 Feb 15. Aliment Pharmacol Ther. 2011. PMID: 21320139 Review.
-
Certolizumab (Cimzia) for Crohn's disease.Med Lett Drugs Ther. 2008 Oct 20;50(1297):81-2. Med Lett Drugs Ther. 2008. PMID: 18927521 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
